Pancreatic Cancer Hero

Pancreatic Cancer

Pancreatic Cancer Clinical Trial

A Prospective Phase II Trial of Molecular Profiling to Guide Neoadjuvant Therapy for Resectable and Borderline Resectable Adenocarcinoma of the Pancreatic Head, Neck or Uncinate Process

Surgeons and oncologists at Froedtert and MCW have developed a unique personalized medicine clinical trial for pancreatic cancer. In this clinical trial a patient’s tumor is tested extensively to identify which chemotherapy treatment has the greatest chance of successfully treating the cancer. It’s being run by Dr. Doug Evans, Dr. Paul Ritch and a team of surgical oncologists and other cancer specialists.


This trial takes a novel, personalized, neoadjuvant approach to treatment of pancreatic cancer. Six specific molecular targets have been identified that are predictive of chemosensitivity to agents commonly used to treat pancreatic cancer today. Investigators will analyze the individual patient's tumor for these molecular target(s) and individualize the neoadjuvant treatment based on the immunohistochemistry and quantitative reverse transcriptase PCR data.

Eligibility/Treatment Schema

Eligible patients include those with known or suspected resectable or borderline resectable adenocarcinoma of the pancreas. Patients will undergo endoscopic ultrasound (EUS)-guided fine needle aspiration (FNA) of their tumors and those samples which are positive for adenocarcinoma will undergo molecular profiling. The patient will then undergo neoadjuvant therapy based on their tumor's molecular profile. If no profile is discernible, the patient will receive neoadjuvant therapy based on current standard of care. Those patients who demonstrate stable disease or treatment response by biochemical, clinical and radiologic measures will be offered resection. The primary objective is to compare resectability rate with targeted neoadjuvant therapy to historical results utilizing neoadjuvant therapy that is non-targeted. Please refer to the treatment schemas: Resectable (Figure A) (PDF) and Borderline Resectable (Figure B) (PDF) and the molecular profiling algorithms: FNA profiling (Figure C) (PDF), Resection Profiling, no previous XRT (Figure D) (PDF), and Resection Profiling, previous XRT (Figure E) (PDF).


If you have specific questions regarding this clinical trial, you may contact any of the following investigators listed below. If you wish to refer a patient for this study, you may contact any one of the individual investigators or schedule the patient through our journey coordinator, Gail Laschen.

Alexandra Rokvic, BS
New Patient Scheduling
Office: (414) 805-6849
Fax: (414) 805-8775

Haley Heaviland
Research Coordinator
Office: (414) 805-8696
Pager: (414) 318-4884
Kathleen Christians, MD
Surgical Oncology
Office: (414) 955-1438
Pager: (414) 557-3979
Fax: (414) 955-0197

Douglas B. Evans, MD
Surgical Oncology
Administrative Office: (414) 955-5706
Clinical Office: (414) 955-1436
Pager: (414) 557-3104
Fax: (414) 955-0197
Paul Ritch, MD
Medical Oncology
Office: (414) 805-4611
Pager: (414) 557-8379
Fax: (414) 805-4606

Ben George, MD
Medical Oncology
Office: (414) 805-4686
Pager: (414) 318-9330
Fax: (414) 805-4606
Beth Erickson, MD
Radiation Oncology
Office: (414) 805-4460
Pager: (414) 557-9418
Fax: (414) 805-4369

Tracy Kelly, MD
Radiation Oncology
Office: (414) 805-4475
Pager: (414) 557-7302
Fax: (414) 805-4369